TICKERNERD
Menu
KODKODHealthcare · Biotechnology

KOD Stock Forecast: Kodiak Sciences, Inc. Price Predictions for 2026-2027

Last close, 2 Oct 2026
$94
−4.07% on the day

The 7 Wall Street analysts covering Kodiak Sciences, Inc. hold a median 12-month price target of $116 — +22.8% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 49 of 100 as at 3 Oct 2026 — in the lower half.

Market cap
$5.9B
Ticker Nerd rank
49 / 100
Median analyst target
$116
Analysts covering
7
Revenue$0.0
Operating income−$66.8M
Net income−$65.6M
Free cash flow−$46.6M
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
+192.0%
1M
+151.9%
YTD
+237.8%
1Y
+603.3%
From 52W high
−4.1%
From 52W low
+714.2%
$12
$98
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

KOD stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Kodiak Sciences, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 3 Oct 2026
49 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Momentum
100
Accruals
88
Value
82
Issuance
68
Revisions
32
Growth
31
Quality
21
Size
21
Volatility
15

Momentum (100): The shares have been drifting up relative to others.

Volatility (15): The share price moves around a lot.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

KOD stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on KOD, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$0$50$100$150Jan 26Apr 26Jul 26Oct 26KODHigh $145Median $116Low $96

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says7 analysts
6 Buy1 Hold0 Sell
Low $96Median $116High $145

The green dot is the last close — the median target sits +22.8% from it.

Recent analyst actionsNewest first

Of the 20 most recent actions, 5 moved their price target up and 0 moved it down.

DateFirmActionRatingTarget
28 Sept 2026HC Wainwright & Co.MaintainsBuy$58 → $96
28 Sept 2026LifeSci CapitalMaintainsOutperform$85 → $145
28 Sept 2026UBSMaintainsBuy$80 → $120
24 Sept 2026Goldman SachsReinstatesNeutral$36
17 Sept 2026HC Wainwright & Co.ReiteratesBuy—
17 Sept 2026HC Wainwright & Co.ReiteratesBuy$58
17 Aug 2026HC Wainwright & Co.ReiteratesBuy$58
17 Aug 2026HC Wainwright & Co.ReiteratesBuy—
3 Aug 2026JP MorganMaintainsOverweight—
3 Aug 2026JP MorganMaintainsOverweight$56 → $66
11 May 2026Chardan CapitalUpgradeBuy—
11 May 2026Chardan CapitalUpgradeBuy$14 → $61
27 Mar 2026HC Wainwright & Co.ReiteratesBuy—
27 Mar 2026UBSMaintainsBuy—
10 Feb 2026HC Wainwright & Co.ReiteratesBuy—
22 Jan 2026HC Wainwright & Co.MaintainsBuy—
7 Jan 2026UBSInitiatesBuy—
17 Nov 2025Chardan CapitalMaintainsNeutral—
17 Nov 2025HC Wainwright & Co.MaintainsBuy—
11 Nov 2025HC Wainwright & Co.UpgradeBuy—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. KOD appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Performance

KOD vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 2 Oct 2026, Kodiak Sciences, Inc. returned +603.3% against +16.2% for the S&P 500, dividends included.

KOD vs S&P 500, last 12 monthsTotal return, rebased to 100
0200400600800Jan 26Apr 26Jul 26Oct 26KODS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

KOD analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
Analysts raising
0
Analysts cutting
5
Fundamentals

Kodiak Sciences, Inc. (KOD) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
−21.9×

Cheaper than 96% of US stocks

Price / sales
—
Price / book
97.0×

Cheaper than 1% of US stocks

EV / EBITDA
−25.3×

Cheaper than 91% of US stocks

Growth & margins
Revenue growth (YoY)
—
Earnings growth (YoY)
—
Gross margin
—
Operating margin
0.0%

Higher than 32% of US stocks

Net margin
0.0%

Higher than 30% of US stocks

Returns & dividend
Return on equity
−368.4%

Higher than 4% of US stocks

Return on assets
−60.4%

Higher than 6% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Key statistics

Kodiak Sciences, Inc. (KOD) statistics: revenue, profit & scale

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • Kodiak Sciences, Inc. has a market value of $5.9B and an enterprise value of $5.9B.

  • Revenue in the twelve months to 30 June 2026: $0.0.

  • Net income over the same four quarters: −$242.0M.

  • Diluted earnings per share, trailing twelve months: $−4.19.

  • Free cash flow in the twelve months to 30 June 2026: −$159.9M.

  • Shares outstanding: 62.8M.

  • Trailing P/E: −21.9×; forward P/E: −25.2× — the forward figure prices analyst consensus estimates, not reported earnings.

  • Kodiak Sciences, Inc. employs 141 people.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 3 Oct 2026

Data provided by Twelve Data

Peers

KOD vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
KODKodiak Sciences, Inc.$5.9B
49
SRRKScholar Rock Holding Corp.$5.7B
35
ORKAOruka Therapeutics, Inc.$5.6B
40
CGONCG Oncology, Inc.$5.9B
17
LGNDLigand Pharmaceuticals, Inc.$6.0B
70
MIRMMirum Pharmaceuticals, Inc.$5.4B
66
TVTXTravere Therapeutics, Inc.$5.4B
86

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Kodiak Sciences, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest KOD news & analysis

Kodiak Sciences' Two Wet AMD Treatments Match Aflibercept in Phase III Study

MarketBeat · 2 Oct 2026positive

Kodiak Sciences reported that its Phase III DAYBREAK study met primary endpoints for two investigational wet AMD treatments in treatment-naïve patients. Both therapies demonstrated statistical equivalence to aflibercept on visual-acuity outcomes.

Why it matters — A Kodiak watcher would care because positive Phase III results for its pipeline candidates in wet AMD support the company's development progress in a major indication.

A $32 Biotech Became a $90 Biotech Overnight. Is It Too Late to Buy Kodiak?

24/7 Wall Street · 30 Sept 2026neutral

Kodiak Sciences' stock tripled in a single session after its eye drug cleared a pivotal trial. However, the company remains a cash-burning biotech with no revenue, and a likely share offering complicates the outlook.

Why it matters — A KOD watcher would care because the drug trial success drove a massive one-day stock surge, but the company's lack of revenue and probable share offering raise questions about the sustainability of the move.

KOD Stock Soars 178% on Positive Wet AMD Data as BLA Filing Nears

Zacks Investment Research · 29 Sept 2026positive

Kodiak Sciences' stock rose 178% following positive phase III DAYBREAK data showing Zenkuda and tabirafusp-ted met key endpoints against Eylea in wet AMD patients. The company is approaching a BLA filing based on these results.

Why it matters — Kodiak watchers would care because the pivotal trial success and nearing BLA filing represent a major advancement for the company's lead wet AMD candidates.

Why Kodiak Sciences Skyrocketed Today

The Motley Fool · 29 Sept 2026positive

Kodiak Sciences shares surged after Zenkuda and KSI-501 hit their primary goals in a Phase 3 study. The global retinal drug market could potentially surpass $32 billion by the end of the decade.

Why it matters — A successful Phase 3 readout for two lead candidates in a large and growing retinal drug market could be a meaningful catalyst for Kodiak's pipeline outlook.

FAQ

Frequently asked questions about KOD stock

What is the KOD stock price forecast for 2026-2027?

The 7 Wall Street analysts covering Kodiak Sciences, Inc. have a median 12-month price target of $116, with estimates ranging from $96 to $145. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is KOD stock a buy right now?

Of the 7 analysts covering Kodiak Sciences, Inc., 6 rate it a Buy, 1 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Kodiak Sciences, Inc. 49 out of 100 across roughly 4,600 US stocks as at 3 Oct 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank KOD?

As at 3 Oct 2026, Kodiak Sciences, Inc. ranks 49 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Momentum (100 of 100).

Will KOD stock go up?

No one can know that. What the data says: the median 12-month target from 7 analysts implies +22.8% from the last close, and Ticker Nerd's factor model ranks Kodiak Sciences, Inc. 49 out of 100 as at 3 Oct 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the KOD stock forecast for 2030?

No analyst covering Kodiak Sciences, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for KOD are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $96 to $145 over the next 12 months.

How has KOD stock performed over the past year?

Kodiak Sciences, Inc. returned +603.3% over the 12 months to 2 Oct 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Kodiak Sciences, Inc. do?

Kodiak Sciences Inc. is a clinical-stage biopharmaceutical company focused on developing therapies for retinal diseases.

What is the latest news on KOD?

The most recent item we track (MarketBeat, 2 Oct 2026): "Kodiak Sciences' Two Wet AMD Treatments Match Aflibercept in Phase III Study". Kodiak Sciences reported that its Phase III DAYBREAK study met primary endpoints for two investigational wet AMD treatments in treatment-naïve patients. Both therapies demonstrated statistical equivalence to aflibercept on visual-acuity outcomes.

Company

About Kodiak Sciences, Inc.

Kodiak Sciences Inc. is a clinical-stage biopharmaceutical company focused on developing therapies for retinal diseases. The company works on treatments for conditions that affect the retina and can lead to vision loss, with a portfolio centered on ophthalmology and retinal vascular disorders. Its current programs include late-stage and earlier-stage candidates built around its proprietary Antibody Biopolymer Conjugate platform, which is designed to support the development of next-generation eye medicines. Kodiak Sciences Inc. serves the biopharmaceutical and ophthalmic research markets by advancing specialized therapeutics for diseases such as wet age-related macular degeneration, diabetic macular edema, retinal vein occlusion, and diabetic retinopathy. Headquartered in Palo Alto, California, and founded in 2009, the company remains focused on researching, developing, and commercializing retina-directed medicines for patients and eye-care specialists.

CEO Dr. Victor Perlroth M.D. · 141 employees · United States · https://kodiak.com